Literature DB >> 20579001

The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates conditioned place preference induced by various addictive and non-addictive drugs in rats.

Kris Rutten1, Elizabeth L Van Der Kam, Jean De Vry, Walter Bruckmann, Thomas M Tzschentke.   

Abstract

We have recently reported that the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates acquisition of conditioned place preference (CPP) induced by heroin and ketamine. The present study investigated to what extent this effect of MPEP can be generalized to other classes of drugs, such as the stimulants nicotine and cocaine, and to drugs that produce CPP in the rat despite a lack of abuse potential in humans, such as buspirone and clonidine. Adult male Sprague Dawley rats were subjected to a standard unbiased CPP protocol (six conditioning sessions lasting 20 minutes for nicotine and 40 minutes for the other compounds). Rats were conditioned with either nicotine (0.05-0.2 mg/kg, subcutaneously), cocaine [1-10 mg/kg, intraperitoneally (i.p.)], buspirone (0.3-3 mg/kg, i.p.) or clonidine (0.2-0.6 mg/kg, i.p.) in combination with MPEP (0 or 10 mg/kg, i.p.). For nicotine and cocaine, the minimal effective dose to induce CPP was lowered by pre-treatment with MPEP. While buspirone and clonidine did not induce CPP when given alone (i.e. combined with MPEP vehicle), both compounds induced CPP after pre-treatment with MPEP. It is concluded that MPEP consistently potentiates acquisition of drug-induced reward, independent of the mechanism of action of the co-administered drug. We suggest that the proposed anti-abuse effect of MPEP may be due to a substitution-like effect.
© 2010 The Authors. Addiction Biology © 2010 Society for the Study of Addiction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20579001     DOI: 10.1111/j.1369-1600.2010.00235.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  18 in total

1.  mGlu receptors and drug addiction.

Authors:  Richard M Cleva; M Foster Olive
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012-01-20

2.  Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.

Authors:  Robert W Gould; Russell J Amato; Michael Bubser; Max E Joffe; Michael T Nedelcovych; Analisa D Thompson; Hilary H Nickols; Johannes P Yuh; Xiaoyan Zhan; Andrew S Felts; Alice L Rodriguez; Ryan D Morrison; Frank W Byers; Jerri M Rook; John S Daniels; Colleen M Niswender; P Jeffrey Conn; Kyle A Emmitte; Craig W Lindsley; Carrie K Jones
Journal:  Neuropsychopharmacology       Date:  2015-08-28       Impact factor: 7.853

3.  Interaction between the mGlu receptors 5 antagonist, MPEP, and amphetamine on memory and motor functions in mice.

Authors:  Francesca Managò; Sebastien Lopez; Alberto Oliverio; Marianne Amalric; Andrea Mele; Elvira De Leonibus
Journal:  Psychopharmacology (Berl)       Date:  2012-11-29       Impact factor: 4.530

Review 4.  Role of cues and contexts on drug-seeking behaviour.

Authors:  Christina J Perry; Isabel Zbukvic; Jee Hyun Kim; Andrew J Lawrence
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

5.  Impact of mGluR5 during amphetamine-induced hyperactivity and conditioned hyperactivity in differentially reared rats.

Authors:  Margaret J Gill; Jennifer C Arnold; Mary E Cain
Journal:  Psychopharmacology (Berl)       Date:  2011-12-06       Impact factor: 4.530

6.  Fragile X mental retardation protein regulates synaptic and behavioral plasticity to repeated cocaine administration.

Authors:  Laura N Smith; Jakub P Jedynak; Miles R Fontenot; Carly F Hale; Karen C Dietz; Makoto Taniguchi; Feba S Thomas; Benjamin C Zirlin; Shari G Birnbaum; Kimberly M Huber; Mark J Thomas; Christopher W Cowan
Journal:  Neuron       Date:  2014-05-07       Impact factor: 17.173

7.  Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography.

Authors:  Funda Akkus; Simon M Ametamey; Valerie Treyer; Cyrill Burger; Anass Johayem; Daniel Umbricht; Baltazar Gomez Mancilla; Judit Sovago; Alfred Buck; Gregor Hasler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

8.  Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction.

Authors:  Russell J Amato; Andrew S Felts; Alice L Rodriguez; Daryl F Venable; Ryan D Morrison; Frank W Byers; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Carrie K Jones; Kyle A Emmitte
Journal:  ACS Chem Neurosci       Date:  2013-05-29       Impact factor: 4.418

Review 9.  The "stop" and "go" of nicotine dependence: role of GABA and glutamate.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Cold Spring Harb Perspect Med       Date:  2013-06-01       Impact factor: 6.915

Review 10.  Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation.

Authors:  Xia Li; Svetlana Semenova; Manoranjan S D'Souza; Astrid K Stoker; Athina Markou
Journal:  Neuropharmacology       Date:  2013-06-07       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.